Spots Global Cancer Trial Database for brigatinib
Every month we try and update this database with for brigatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | NCT03719898 | Anaplastic Larg... | Brigatinib | 18 Years - | Fox Chase Cancer Center | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) | NCT01449461 | Lymphoma, Large... Carcinoma, Non-... | Brigatinib | 18 Years - | Takeda | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | NCT04374305 | Neurofibromatos... Vestibular Schw... Non-vestibular ... Meningioma Ependymoma | Brigatinib Neratinib | 12 Years - | Massachusetts General Hospital | |
| Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT03707938 | Advanced Lung C... ALK Gene Rearra... Lung Non-Small ... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Brigatinib Local Consolida... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | NCT03737994 | Lung Non-Squamo... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alectinib Brigatinib Carboplatin Ceritinib Cisplatin Crizotinib Ensartinib Lorlatinib Pemetrexed | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | NCT02094573 | Carcinoma, Non-... | Brigatinib | 18 Years - | Takeda | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors | NCT04925609 | Anaplastic Larg... Inflammatory My... Other Solid Tum... | Brigatinib | 1 Year - 25 Years | Princess Maxima Center for Pediatric Oncology | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | NCT04318938 | NSCLC | Brigatinib Tyrosine kinase... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | NCT03535740 | ALK-positive Ad... | Brigatinib | 18 Years - | Takeda | |
| Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT03707938 | Advanced Lung C... ALK Gene Rearra... Lung Non-Small ... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Brigatinib Local Consolida... | 18 Years - | M.D. Anderson Cancer Center | |
| Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT03707938 | Advanced Lung C... ALK Gene Rearra... Lung Non-Small ... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Brigatinib Local Consolida... | 18 Years - | M.D. Anderson Cancer Center | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer | NCT03596866 | ALK+ Advanced N... | Brigatinib Alectinib | 18 Years - | Takeda | |
| Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors | NCT04260009 | Anaplastic Lymp... Inflammatory My... Solid Tumors | Brigatinib Brigatinib AAF | 1 Year - 25 Years | Takeda | |
| A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. | NCT05361564 | Non-small Cell ... | Brigatinib | 20 Years - | Yonsei University | |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | NCT04005144 | ALK Gene Rearra... Lung Non-Small ... Progressive Dis... ROS1 Gene Rearr... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Binimetinib Brigatinib | 18 Years - | University of California, San Francisco | |
| Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer | NCT05100069 | Non-small Cell ... | Brigatinib | - | Takeda | |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients | NCT04223596 | Lung Cancer NSCLC NSCLC Stage III... NSCLC Stage IV | Brigatinib | 18 Years - | Fundación GECP | |
| Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases | NCT03389399 | Non-Small Cell ... | 18 Years - 100 Years | University of Colorado, Denver | ||
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) | NCT01449461 | Lymphoma, Large... Carcinoma, Non-... | Brigatinib | 18 Years - | Takeda | |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | NCT04005144 | ALK Gene Rearra... Lung Non-Small ... Progressive Dis... ROS1 Gene Rearr... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Binimetinib Brigatinib | 18 Years - | University of California, San Francisco | |
| Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC | NCT04227028 | Locally Advance... Metastatic Lung... Recurrent Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Bevacizumab Brigatinib | 18 Years - | City of Hope Medical Center | |
| Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) | NCT03410108 | ALK-positive Ad... | Brigatinib | 20 Years - | Takeda | |
| Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | NCT04318938 | NSCLC | Brigatinib Tyrosine kinase... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients | NCT04223596 | Lung Cancer NSCLC NSCLC Stage III... NSCLC Stage IV | Brigatinib | 18 Years - | Fundación GECP | |
| An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | NCT02784158 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib | 18 Years - | Takeda | |
| Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer | NCT05718297 | NSCLC, Stage II... ALK-rearrangeme... | Brigatinib Durvalumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | NCT02706626 | Non-Small Cell ... | brigatinib | 18 Years - | Criterium, Inc. | |
| Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays | NCT04074993 | Non Small Cell ... | Brigatinib | 18 Years - | National Cancer Center, Korea | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | NCT03868423 | Advanced Malign... ALK Fusion Prot... ALK Gene Amplif... ALK Gene Mutati... Locally Advance... Metastatic Mali... Metastatic Mali... Metastatic Mali... ROS1 Fusion Pos... ROS1 Gene Ampli... ROS1 Gene Mutat... | Brigatinib Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases | NCT03389399 | Non-Small Cell ... | 18 Years - 100 Years | University of Colorado, Denver | ||
| Brigatinib Before Brain Irradiation Trial (B3i Trial) | NCT04634110 | Brain Metastase... Lung Cancer | Brigatinib | 18 Years - | University of Colorado, Denver | |
| Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) | NCT03410108 | ALK-positive Ad... | Brigatinib | 20 Years - | Takeda | |
| A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | NCT03535740 | ALK-positive Ad... | Brigatinib | 18 Years - | Takeda | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | NCT04374305 | Neurofibromatos... Vestibular Schw... Non-vestibular ... Meningioma Ependymoma | Brigatinib Neratinib | 12 Years - | Massachusetts General Hospital | |
| Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer | NCT05100069 | Non-small Cell ... | Brigatinib | - | Takeda | |
| A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | NCT03535740 | ALK-positive Ad... | Brigatinib | 18 Years - | Takeda | |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | NCT05200481 | Non Small Cell ... ALK Gene Mutati... | Brigatinib 180 ... Carboplatin Pemetrexed | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer | NCT05100069 | Non-small Cell ... | Brigatinib | - | Takeda | |
| An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | NCT02784158 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
